Virax Biolabs Group (VRAX) Stock Overview
A biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VRAX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Virax Biolabs Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.87 |
| 52 Week High | US$9.00 |
| 52 Week Low | US$0.74 |
| Beta | 1.64 |
| 1 Month Change | -11.46% |
| 3 Month Change | -1.66% |
| 1 Year Change | -22.64% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.52% |
Recent News & Updates
Shareholder Returns
| VRAX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 3.1% | -5.0% | 0.4% |
| 1Y | -22.6% | -19.5% | 12.5% |
Return vs Industry: VRAX underperformed the US Healthcare industry which returned -19.5% over the past year.
Return vs Market: VRAX underperformed the US Market which returned 12.5% over the past year.
Price Volatility
| VRAX volatility | |
|---|---|
| VRAX Average Weekly Movement | 11.5% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: VRAX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRAX's weekly volatility has decreased from 31% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 19 | James Foster | viraxbiolabs.com |
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women’s health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents.
Virax Biolabs Group Limited Fundamentals Summary
| VRAX fundamental statistics | |
|---|---|
| Market cap | US$3.73m |
| Earnings (TTM) | -US$6.06m |
| Revenue (TTM) | US$6.33k |
Is VRAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRAX income statement (TTM) | |
|---|---|
| Revenue | US$6.33k |
| Cost of Revenue | US$59.40k |
| Gross Profit | -US$53.07k |
| Other Expenses | US$6.01m |
| Earnings | -US$6.06m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.40 |
| Gross Margin | -838.21% |
| Net Profit Margin | -95,739.17% |
| Debt/Equity Ratio | 6.8% |
How did VRAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/08 21:56 |
| End of Day Share Price | 2025/07/08 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Virax Biolabs Group Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Kerr | Zacks Small-Cap Research |